Interferon-αCon1 suppresses proliferation of liver cancer cell lines in vitro and in vivo

Journal of Hepatology

Volumn 41, Issue 5, 2004, Pages 782-789

  Hisaka, Toru ^a   Yano, Hirohisa ^a   Ogasawara, Sachiko ^a   Momosaki, Seiya ^a   Nishida, Naoyo ^a   Takemoto, Yumi ^a   Kojiro, Sakiko ^a   Katafuchi, Yuno ^a   Kojiro, Masamichi ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Angiogenesis; Antiproliferation; Apoptosis; Consensus interferon; Hepatocellular carcinoma; Nude mouse

Indexed keywords

CONSENSUS INTERFERON; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; INTERFERON ALFACON-1; RECOMBINANT INTERFERON;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BLOOD VESSEL; CANCER CELL CULTURE; CANCER INHIBITION; CANCER PREVENTION; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HEPATITIS C; HISTOLOGY; HUMAN; HUMAN CELL; LIVER CANCER; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; TUMOR VOLUME; ANIMAL; BAGG ALBINO MOUSE; BILE DUCT CARCINOMA; BILE DUCT TUMOR; CELL DIVISION; DRUG EFFECT; IN VITRO STUDY; INTRAHEPATIC BILE DUCT; LIVER TUMOR; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; APOPTOSIS; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CARCINOMA, HEPATOCELLULAR; CELL DIVISION; CELL LINE, TUMOR; CHOLANGIOCARCINOMA; HUMANS; INTERFERON TYPE I, RECOMBINANT; LIVER NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE;

EID: 7244226606     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2004.07.012     Document Type: Article

References (46)

1. C. Bréchot, F. Jaffredo, D. Lagorce, G. Gerken, K.M. Büchenfelde, and A. Papakonstoninou Impact of HBV, HCV and GBV-C/HGV on hepatocellular carcinoma in Europe: results of a European concerted action J Hepatol 29 1998 173 183
2. A.M. Di Bisceglie, S.E. Order, J.L. Klein, J.G. Waggoner, M.H. Sjogren, and G. Kuo The role of chronic viral hepatitis in hepatocellular carcinoma in the United States Am J Gastroenterol 86 1991 335 338
3. Y. Shiratori, S. Shiina, M. Imamura, N. Kato, F. Kanai, and T. Okudaira Characteristic difference of hepatocellular carcinoma between hepatitis B- and C-viral infection in Japan Hepatology 22 1995 1027 1033
4. J.U. Gutterman Cytokine therapeutics: Lessons from interferon-α Proc Natl Acad Sci USA 91 1994 1198 1205
5. K. Ikeda, S. Saitoh, Y. Arase, K. Chayama, Y. Suzuki, and M. Kobayashi Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: A long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis Hepatology 29 1999 1124 1130
6. G. Mazzella, E. Accogli, S. Sottili, D. Festi, M. Orsini, and A. Salzetta Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis J Hepatol 24 1996 141 147
7. S. Nishiguchi, T. Kuroki, S. Nakatani, H. Morimoto, T. Takeda, and S. Nakajima Randomised trial of effects of interferon-α on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis Lancet 346 1995 1051 1055
8. G.R. Stark, I.M. Kerr, B.R. Williams, R.H. Silverman, and R.D. Schreiber How cells respond to interferons Annu Rev Biochem 67 1998 227 264
9. D. Xu, S. Erickson, M. Szeps, A. Gruber, O. Sangfelt, and S. Einhorn Interferon α down-regulates relomerase reverse transcriptase and telomerase activity in human malignant and nonmalignant hempatopoietic cells Blood 96 2000 4313 4318
10. S. Negrier, B. Escudier, C. Lasset, J.Y. Douillard, J. Savary, and C. Chevreau Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie N Engl J Med 338 1998 1272 1278
11. B.E. Huber, P.J. Wirth, and J.E. Newbold Effects of human lymphoblastoid interferon on proliferation, gene expression and tumourigenicity of human hepatoma cell lines Drugs Exp Clin Res 17 1991 281 291
12. A.A. Dunk, T. Ikeda, M. Pignatelli, and H.C. Thomas Human lymphoblastoid interferon: in vitro and in vivo studies in hepatocellular carcinoma J Hepatol 2 1986 419 429
13. H. Yano, A. Iemura, M. Haramaki, S. Ogasawara, A. Takayama, and J. Akiba Interferon alfa receptor expression and growth inhibition by interferon alfa in human liver cancer cell lines Hepatology 29 1999 1708 1717
14. D. Murphy, K.M. Detjen, M. Welzel, B. Wiedenmann, and S. Rosewicz Interferon-alpha delays S-phase progression in human hepatocellular carcinoma cells via inhibition of specific cyclin-dependent kinases Hepatology 33 2001 346 356
15. A.E. Milner, R.J. Grand, and C.D. Gregory Effects of interferon-alpha on human B cells: Repression of apoptosis and prevention of cell growth are independent responses of Burkitt lymphoma lines Int J Cancer 61 1995 348 354
16. M. Torcia, M. Lucibello, G. De Chiara, D. Labardi, L. Nencioni, and P. Bonini Interferon-alpha-induced inhibition of B16 melanoma cell proliferation: interference with the bFGF autocrine growth circuit Biochem Biophys Res Commun 262 1999 838 844
17. R. Thulasi, P. Dias, P.J. Houghton, and J.A. Houghton Alpha 2a-interferon-induced differentiation of human alveolar rhabdomyosarcoma cells: correlation with down-regulation of the insulin-like growth factor type I receptor Cell Growth Differ 7 1996 531 541
18. O. Sangfelt, S. Erickson, J. Castro, T. Heiden, S. Einhorn, and D. Grandér Induction of apoptosis and inhibition of cell growth are independent responses to interferon-α in hematopoietic cell lines Cell Growth Differ 8 1997 343 352
19. J. Rodríuez-Villanueva, and T.J. MacDonnell Induction of apoptotic cell death in non-melanoma skin cancer by interferon-α Int J Cancer 61 1995 110 114
20. C. Selleri, T. Sato, L.D. Vecchio, L. Luciano, A.J. Barrett, and B. Rotoli Involvement of Fas-mediated apoptosis in the inhibitory effects of interferon-α in chronic myelogenous leukemia Blood 89 1997 957 964
21. D. Melamed, N. Tiefenbrun, A. Yarden, and A. Kimchi Interferons and interleukin-6 suppress the DNA-binding activity of E2F in growth-sensitive hematopoietic cells Mol Cell Biol 13 1993 5255 5265
22. 1 arrest in the inhibition of tumor cell growth by interferon Proc Natl Acad Sci USA 77 1980 1471 1475
23. G. Roos, T. Leanderson, and E. Lundgren Interferon-induced cell cycle changes in human hematopoietic cell lines and fresh leukemic cells Cancer Res 44 1984 2358 2362
24. Y. Numa, K. Kawamoto, N. Sakai, and H. Matsumura Flow cytometric analysis of antineoplastic effects of interferon-α, β and γ labelled with fluorescein isothiocyanate on cultured brain tumors J Neuro-Oncol 11 1991 225 234
25. T.G. Nikolaeva, I.V. Timofeev, and Ia.V. Dobrynin Effect of interferon on cell cycle phases in cultured human tumor cells Eksp Onkol 6 1984 52 55
26. Kip1 that prevent activation of cyclin-dependent kinase by CDK-activating kinase (CAK) Oncogene 16 1998 217 225
27. L.M. Blatt, J.M. Davis, S.B. Klein, and M.W. Taylor The biologic activity and molecular characterization of a novel synthetic interferon-alpha species, consensus interferon J Interferon Cytokine Res 16 1996 489 499
28. O.N. Ozes, Z. Reiter, S. Klein, L.M. Blatt, and M.W. Taylor A comparison of interferon-Con1 with natural recombinant interferons-alpha: antiviral, antiproliferative, and natural killer-inducing activities J Interferon Res 12 1992 55 59
29. S.B. Klein, L.M. Blatt, and M.W. Taylor Cell surface binding characteristics correlate with consensus type I interferon enhanced activity J Interferon Cytokine Res 16 1996 1 6
30. T. Murakami Establishment and characterization of human hepatoma cell line (KIM-1) Acta Hepatol Jpn 25 1984 532 539
31. H. Yano, M. Kojiro, and T. Nakashima A new human hepatocellular carcinoma cell line (KYN-1) with a transformation to adenocarcinoma In Vitro Cell Dev Biol 22 1986 637 646
32. H. Yano, M. Maruiwa, T. Murakami, K. Fukuda, Y. Ito, and S. Sugihara A new human pleomorphic hepatocellular carcinoma cell line, KYN-2 Acta Pathol Jpn 38 1988 953 966
33. T. Murakami, M. Maruiwa, K. Fukuda, M. Kojiro, M. Tanaka, and K. Tanikawa Characterization of a new human hepatoma cell line (KYN-3) derived from the ascites of the hepatoma patient [Abstract] Jpn J Cancer Res 1988 292 Proceedings of the Japanese Cancer Association
34. H. Yano, A. Iemura, K. Fukuda, A. Mizoguchi, M. Haramaki, and M. Kojiro Establishment of two distinct human hepatocellular carcinoma cell lines from a single nodule showing clonal dedifferentiation of cancer cells Hepatology 18 1993 320 327
35. M. Haramaki, H. Yano, A. Iemura, S. Momosaki, S. Ogasawara, and M. Inoue A new human hepatocellular carcinoma cell line (HAK-2) forms various structures in collagen gel matrices Hum Cell 10 1997 183 192
36. T. Murakami, H. Yano, M. Maruiwa, S. Sugihara, and M. Kojiro Establishment and characterization of a human combined hepatocholangiocarcinoma cell line and its heterologous transplantation in nude mice Hepatology 7 1987 551 556
37. H. Yano, A. Iemura, M. Haramaki, S. Momosaki, S. Ogasawara, and K. Higaki A human combined hepatocellular and cholangiocarcinoma cell line (KMCH-2) that shows the features of hepatocellular carcinoma or cholangiocarcinoma under different growth conditions J Hepatol 24 1996 413 422
38. C.P. Dinney, D.R. Bielenberg, P. Perrotte, R. Reich, B.Y. Eve, and C.D. Bucana Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-alpha administration Cancer Res 58 1998 808 814
39. Y.K. Hong, D.S. Chung, Y.A. Joe, Y.J. Yang, K.M. Kim, and Y.S. Park Efficient inhibition of in vivo human malignant glioma growth and angiogenesis by interferon-beta treatment at early stage of tumor development Clin Cancer Res 6 2000 3354 3360
40. C.L. Lai, J.Y.N. Lau, P. Wu, H. Ngan, H.T. Chung, and S.J. Mitchell Recombinant interferon-α in inoperable hepatocellular carcinoma: a randomized controlled trial Hepatology 17 1993 389 394
41. E. Sachs, A.M. Di Bisceglie, G.M. Dusheiko, E. Song, S.F. Lyons, and B.D. Schoub Treatment of hepatocellular carcinoma with recombinant leucocyte interferon: a pilot study Br J Cancer 52 1985 105 109
42. The Gastrointestinal Tumor Study Group A prospective trial of recombinant human interferon alpha 2B in previously untreated patients with hepatocellular carcinoma Cancer 66 1990 135 139
43. J.M. Llovet, M. Sala, L. Castells, Y. Suarez, R. Vilana, L. Bianchi, and C. Ayuso Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma Hepatology 31 2000 54 58
44. P. Merle, L. Barraud, L. Lefranois, M. Chevallier, S. Guerret, and M. Maisonnas Lont-term high-dose interferon-α therapy delays Hepadnavirus-related hepatocarcinogenesis in X/myc transgenic mice Oncogene 22 2003 2762 2771
45. P. Merle, M. Chevallier, R. Levy, M. Maisonnas, O. Terradillos, and S. Si Ahmed Preliminary results of interferon-α therapy on woodchuck hepatitis virus-induced hepatocarcinogenesis: possible benefit in female transgenic mice J Hepatol 34 2001 562 569
46. M. Alvarez, J. Cerliani, J. Monti, C. Carnovale, M. Ronco, and G. Pisani The in vivo apoptotic effect of interferon alfa-2b on rat preneoplastic liver involves bax protein Hepatology 35 2002 824 833